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incidence of chronic kidney disease in young
adults with impaired glucose tolerance
Ferozkhan Jadhakhan*, Tom Marshall and Paramjit GillAbstract
Background: It is known that risk of chronic kidney disease (CKD) is elevated in patients with diabetes mellitus
but it is not clear whether the risk is also elevated with impaired glucose tolerance (IGT). If the risk is increased, it is
not known if this is confined to people with IGT who progress to type 2 diabetes (T2DM). The purpose of this
systematic review is to determine the relative risk of CKD in young adults (aged 18 to 40 years) with IGT (exposed
group) compared to those without glycaemic abnormality (comparator group).
Methods/Design: The following electronic databases will be systematically searched from inception to January
2015 for relevant studies: CINAHL, EMBASE, MEDLINE, PubMed, Cochrane libraries and grey literature. Two
independent reviewers will screen search results, extract data, select studies for inclusion and assess their quality.
Studies including young adults (aged 18 to 40 years) with IGT containing any of the following CKD markers will be
included: estimated glomerular filtration rate (eGFR), albumin creatinine ratio (ACR), protein creatinine ratio (PCR),
serum creatinine (SCr) and creatinine clearance (CrCl) levels. Studies at any time period after diagnosis of IGT and
with any length of follow-up will be included. The proportion of IGT participants reporting each outcome will be
documented. Relative risks (RR) and odds ratios (OR) will be extracted or calculated from raw data. If possible, study
results will be combined in a meta-analysis.
Discussion: The results of this comprehensive review will establish the evidence for the association between IGT
and the risk of developing CKD in young adults (aged 18 to 40 years).
Systematic review registration: PROSPERO CRD42014007081
Keywords: Impaired glucose tolerance, Chronic kidney disease, Estimated glomerular filtration rate, Albumin
creatinine ratio, Protein creatinine ratio, Serum creatinine, Creatinine clearance, Type 2 diabetes and young adultsBackground
Chronic kidney disease (CKD) is a long-term condition
which may lead to renal failure or in some cases to pre-
mature death if left undetected. CKD is characterised by
the presence of kidney damage (albuminuria) and/or a
gradual loss of kidney function (eGFR) over time [1].
The complex interrelationship of CKD and its associated
comorbidities render this condition a substantial public
health concern [2]. Furthermore, CKD is an independent
risk factor for cardiovascular disease (CVD) [3]. Diabetes
is the leading cause of chronic kidney disease and end* Correspondence: FXJ733@bham.ac.uk
Primary Care Clinical Sciences, University of Birmingham, Birmingham B15
2TT, UK
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unless otherwise stated.stage renal disease (ESRD). CKD is present in 40 % of in-
dividuals with a history of diabetes compared to 15 % of
individuals with no history of diabetes [4]. A recent study
conducted in the UK showed that the risk of developing
CKD (stages 3B, 4 and 5) in people with diabetes was eight
times higher in women and over 12 times higher in men
compared to those without diabetes [5].
On the other hand, impaired glucose tolerance (IGT) rep-
resents an intermediate state of normal glucose homeostasis
and diabetic hyperglycaemia. Individuals who are classed as
IGT have a blood sugar level raised beyond normal level,
but it is not high enough to suggest full blown diabetes [6].
The prospective association of CKD with IGT has not been
fully established. Cross-sectional data show some associationtral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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kidney function which may result in kidney disease and lead
to kidney failure [7–9]. It is not clear whether the risk of
CKD is also elevated in IGT. The current American Dia-
betes Association (ADA) definition of IGT is: fasting plasma
glucose of 100–125 mg/dL (5.6–6.9 mmol/L), a blood glu-
cose of 140–198 mg/dL (7.8–11.1 mmol/L) after a 2-h oral
glucose tolerance test (OGTT) and a glycated haemoglobin
(HbA1c) of 5.7–6.4 % (39–47 mmol/mol) [10]. Not every-
one with IGT progresses to type 2 diabetes (T2DM); how-
ever, people with high glucose level are at greater risk of
progressing to T2DM and subsequently develop CKD. A
published analysis using data from the general practice
research database (GPRD) estimated the prevalence of IGT/
impaired fasting glucose (IFG) from a study population of
approximately 2.8 million individuals registered with a GP
practice between 1 January 2000 and April 2005. The
annual prevalence of IGT/IFG during the 5-year study
period increased from 17 cases per 100,000 individuals in
2001 to 31 cases per 100,000 individuals in 2005 [11].
Risk of CKD amongst young adults (aged 18 to 40 years)
with IGT
In a cross-sectional study of adult aged ≥25 years, the
prevalence of albuminuria, an early marker for the devel-
opment of CKD, was 5.1 % with normal glucose toler-
ance, 11 % with IGT, 17.8 % newly diagnosed and 36.2 %
known type 2 diabetes [12]. Similarly, in the data from
the US National Health and Nutrition Examination Sur-
vey (NHANES) from 1999 to 2006, the prevalence of
CKD was found to be 39.6 % in self-reported diagnosed
diabetes, 41.7 % in previously undiagnosed diabetes (fast-
ing plasma glucose [FPG] ≥126 mg/dL), 17.7 % in pre-
diabetes (IGT ≥100 and <126 mg/dL) and 10.6 % in those
without glycaemic abnormality [13]. These cross-sectional
data are however subject to some limitations. It is unclear
whether CKD precedes impaired glucose metabolism or
vice versa (Fig. 1) and eGFR values were taken on only a
single occasion.
IGT trajectory and the development of CKD in young
adults (aged 18 to 40 years)
Two epidemiological studies in Native American popula-
tions found evidence linking renal function to IGT. One
found similar rates of decline in glomerular filtration rate
(GFR) over 4 years in persons with IGT (14 % decline) and
with newly diagnosed diabetes (18 % decline) [14]. The
other found 15 % of the 934 non-diabetic participants had
micro-albuminuria [15]. In contrast, in the data derived
from the Framingham heart study offspring cohort (1991–
1995) examining the development of CKD (eGFR <59 mL/
min/1.73 m2 in women and <64 mL/min/1.73 m2 in men)
after patients were given an oral glucose tolerance test and
followed up for an average 7 years, the subsequent meanGFR at follow-up were: normoglycaemia (87 ml/min/1.73
m2), IGT (85 ml/min/1.73 m2), newly diagnosed diabetes
(82 ml/min/1.73 m2) and know diabetes (78 ml/min/1.73
m2) [16]. As many studies have used a single determination
of glycaemic status at baseline, it is not clear whether the
risk of developing a CKD event is confined to people with
IGT who progress to overt diabetes or whether the risk is
still increased amongst people with IGT even if they never
develop diabetes. Few studies have included young adults
(aged 18 to 40 years) with IGT in their analyses. Studies
that included individuals aged ≥18 years were cross-
sectional by design and are subject to some limitations.
This makes the determination of relative risk and incidence
of CKD impossible. Also, it is unclear whether CKD pre-
ceded impaired glucose tolerance metabolism and eGFR
values were measured on only a single occasion. Further-
more, some changes in the renal function (e.g. decrease
glomerular filtration rate and increased albuminuria) may
already be present in individuals with IGT before the onset
of diabetes. Due to these limitations, it is inappropriate to
extrapolate rates and relative risks to this cohort of individ-
uals and in particular to primary care where majority of
decisions for early prevention are made. It is therefore
important to have a reliable estimate of the incidence of
CKD in this cohort of individuals.
The overall purpose of this systematic review is to elu-
cidate whether the presence of IGT is associated with an
increased risk of CKD by comparing the risk of CKD in
individuals with IGT to those without IGT.
Aims
This systematic review will aim to:
 Determine the incidence of CKD in young adults
(aged 18 to 40 years) with IGT.
 Determine the relative risk of developing CKD in
young adults (aged 18 to 40 years) with IGT
(exposed group) compared to those without
glycaemic abnormality (comparator group).
 Determine whether the risk of CKD (compared to
people without IGT) is increased in the subgroup of
IGT patients who develop type 2 diabetes (T2DM)
vs. IGT patients who do not develop T2DM. If data
permits to examine whether there is any increasing
CKD risk gradient across the three subgroups:
unexposed group (people without IGT or diabetes),
exposed group 1 (people with IGT but without
diabetes) and exposed group 2 (people who have
both IGT and diabetes).
Methods/Design
Established guidelines for reviews will be used to inform
the search strategy, for the selection of studies, assess-
ment of risks of bias and reporting of results [17, 18].
Normo-
Glycaemic
IGT
CKD
Diabetes 
Mellitus (Type 
2)
CKD + Diabetes 
Mellitus
CKD + IGT
Fig. 1 Progression of impaired glucose tolerance to type 2 diabetes or reversal to normoglycaemia and development of chronic kidney disease.
IGT: impaired glucose tolerance; T2DM: type 2 diabetes; CKD: chronic kidney disease
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Types of participants and comparison group
This review will include studies of participants aged 18
to 40 years without a diagnosis of type 1 and type 2 dia-
betes but with IGT, “Pre-diabetes” or “Pre-diabetic
state”. Pre-diabetes can refer to either IGT or IFG [19],
or metabolic syndrome where IGT is part of the meta-
bolic syndrome. The comparison group will be either
participants with normoglycaemia or diabetic partici-
pants. For the purpose of this review, IGT will be de-
fined as a FPG <7 mmol/L or an OGTT ≥7.8 mmol/L
and <11.1 mmol/L, or HbA1c of 6.0–6.4 % (42–47
mmol/mol) [20].
Participants and outcomes—cohort studies This re-
view will include any cohort studies where some partici-
pants are aged 18 to 40 years; results are reported
separately in this age group with:
1) IGT but without a diagnosis of type 1 or type 2
diabetes compared to participants without glycaemic
abnormality.
2) IGT but without a diagnosis of type 1 diabetes
compared to participants with T2DM.
Exposed (cases with IGT) and comparator (without gly-
caemic abnormality or T2DM) groups must be free from
CKD at baseline. Studies will be included that define
chronic kidney disease by any of a number of measures.
These include eGFR stages 3A, 3B, 4 and 5; albuminuria; al-
bumin creatinine ratio (ACR ≥2.5 mg/mmol or ≥30 mg/g),
protein creatinine ratio (PCR ≥45 mg/mmol or ≥300 mg/g),
serum creatinine (SCr 1.0 mg/dL or ≥50 μmol/L) and cre-
atinine clearance (CrCl ≥60 ml/min). Studies that report
mean changes in continuous variables (e.g. eGFR) will be
included and findings summarised separately. The inci-
dence of CKD during follow-up must be reported or calcul-
able in both exposed and comparator groups. Studies must
either report relative risk for the above outcomes or the
incidence of CKD must be reported or calculable from rawdata in exposed and comparator groups allowing relative
risk (RR) to be calculated. There will be no restriction on
the length of participant follow-up.
Participants and outcomes—case control studies This
review will also include any case control studies where
some cases are (aged 18 to 40 years) with an incident
diagnosis of CKD (the outcome of interest) by any of the
above definitions (eGFR stages 3A or higher; albumin-
uria; ACR, PCR, SCr and CrCl) and controls without a
diagnosis of CKD. In the case control studies, the fre-
quency of previous IGT (exposure to IGT) must be re-
ported or calculable in both cases and controls and
compared either to the frequency of normoglycaemia
(unexposed) or to the frequency of diabetes (an alterna-
tive exposure). There will be no restriction on the length
of time between CKD diagnosis and exposure in case–
control studies. Studies must either report odds ratios or
this must be calculable from the raw data extracted from
the study.
Exclusion criteria
Studies without a formal comparison group or control
arm will be excluded from the review. Cross-sectional
studies will be excluded because they do not distinguish
between IGT diagnosed after CKD and IGT diagnosed
before CKD. Randomised controlled trial including quasi-
experimental designs will also be excluded.
Sources of information
The following electronic databases will be systematically
searched from inception to January 2015: MEDLINE, Cu-
mulative Index to Nursing and Allied Health Literature
(CINAHL), EMBASE, PubMed, Database of Abstracts of
Reviews of Effects (DARE), Cochrane Database of System-
atic Reviews (CDSR) and Trip Database. Furthermore, on-
going studies, scientific literature and abstract proceedings
will be identified by searching the following databases:
ClinicalTrials.gov, Cochrane Renal Group specialised regis-
ter, Renal Registry Database, British Renal Society, Renal
Table 1 Review eligibility criteria checklist
Study design Cohort studies
Case–control studies
Study characteristics Full articles
Conference proceedings
Grey literature
Theses/dissertations
Other (please specify)
Participants Studies where some participants are
aged 18 to 40 years
With IGT
With pre-diabetes (can refer to either
IGT or impaired fasting glucose (IFG)
With metabolic syndrome (where IGT
is part of metabolic syndrome)
Free from CKD at baseline
Comparator Participant with normoglycaemia
Participants with diabetes
Outcome Chronic kidney disease [eGFR stages:
3A, 3B, 4 and 5]
Albuminuria
ACR (albumin creatinine ratio ≥30 mg/mmol
PCR (protein creatinine ratio ≥50 mg/mmol
SCr (serum creatinine) data
CrCl (creatinine clearance) data
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gress of Nephrology, Diabetes UK Conference, Primary
Care Diabetes Society Conference and Zetoc. A compre-
hensive search of the Conference Proceedings Citation
Index (CPCI) will also be carried out. Search of these data-
bases will span from January 2011 to January 2014 as it is
likely that studies would have been completed and pub-
lished. Grey literature databases, such as Grey Literature
Report, OpenGrey, PubliCat and ScienceDaily.com will be
examined. Google Scholar will also be explored; a scoping
search revealed that the most pertinent articles were found
in the first ten pages of the searches. Open access theses
and dissertations will be retrieved from the ProQuest Dis-
sertation Thesis Database and thesis.com. The Science Cit-
ation Index (SCI) will be used to scan and track study titles.
Search
An optimal search strategy has been developed; an add-
itional file shows this in more details (see Additional file
1) which focuses on the following key terms: chronic
kidney disease, impaired glucose tolerance, type 2 dia-
betes and young adult.
Study selection process
Two reviewers will independently review all titles and
abstract of the search results in two phases. First, the
retrieved titles and abstracts will be reviewed to identify
relevant studies. Then, the full text of retrieved studies will
be read to determine eligibility. Any discrepancies or
difference in opinion will be resolved by consensus or by
involving a third reviewer. An inclusion criteria checklist
(Table 1) has been developed based on study eligibility cri-
teria and piloted on five papers to check that studies are
interpreted and classified appropriately. A PRISMA study
flow diagram of included and excluded studies will be pro-
vided along with reasons for exclusion.
Data collection process
A data extraction form has been designed based on the
Hayden et al. framework [21]; this is described in more
details in an additional file (see Additional file 2). This form
has been iteratively developed and will be pilot tested on
known papers independently by two reviewers. The form
has been designed to focus on population, comparator, out-
come and study design. Data extraction will be conducted
by one reviewer and checked by another for all studies iden-
tified through the screening phase. Errors in data extraction
will be discussed and amended as required. For missing
data, authors may be contacted for clarification. A Micro-
soft Excel sheet will be used to manage data extraction.
Quality assessment
Quality assessment will be carried out by two reviewers
independently. Difference in opinion will be resolved byconsensus or by involving a third reviewer, if necessary.
Study quality will be assessed by focusing on the follow-
ing criteria: sampling, validated method to confirm out-
come, attrition and analytical method. The form has
been adapted from the Ottawa–Newcastle Scale (NOS)
[22] to assess the quality of cohort and case–control
studies to meet the specific needs of this systematic re-
view. An additional file describes the stages and domain
of this modified tool (see Additional file 3). The devised
form has been assessed independently by two reviewers
on known papers to ascertain its viability. Presentation
of risk of bias assessment will be displayed in accordance
with the Cochrane Collaboration recommendation. A
composite score will not be provided; instead, a risk of
bias of “yes” indicating low risk, “no”, high risk and “un-
clear” will be given to assess each domain [23]. A narra-
tive summary of the overall quality of each study will be
provided in a table. A critical appraisal of the study qual-
ity will be discussed along with the impact of the quality
of studies on results. Studies rated poor quality will be
excluded by conducting a sensitivity analysis.
Data synthesis
Adjusted or unadjusted covariates, odds ratios (OR) or
RR will be extracted or calculated from data provided.
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normoglycaemia or type 2 diabetes. In case–control
studies, participants with an incident diagnosis of CKD
(cases) will be compared to participants without a diagno-
sis of CKD (controls). Data will be grouped and presented
separately according to the study design. This will be pre-
sented in tables. If appropriate, cohort and case–control
studies will be grouped separately and pooled estimates of
the OR/RR for CKD compared to normoglycaemia and
compared to diabetes will be calculated using STATA.
Subgroup analyses may be performed if studies explore
risks across groups for example: sex (female vs male),
ethnicity (Black/Asians/other and White populations), age
(≥18 ≤ 40) and adjustment for CKD comorbidities (e.g.
hypertension, dyslipidaemia cardiovascular diseases and
triglyceride). This will allow risk of CKD to be compared
across these subgroups. Depending on the level of hetero-
geneity, both fixed and random effect models will be used
as summary effect measure. A sensitivity analysis will be
performed to examine the robustness of the meta-analysis
under different assumptions: 1) will the result change if
small sample size studies are removed, and 2) for studies
which OR/RR were not provided and were calculated
from raw data, will results of the pooled analysis change if
these are removed. Risk ratio measures with 95 % confi-
dence interval (CI) will be calculated for binary outcomes
(e.g. incidence of CKD) or standardise mean difference
with accompanying 95 % CI where continuous scales of
measurements were used to identify CKD markers. If pos-
sible, CKD markers will be grouped into clinical stages
based on GFR (3A, 3B, 4, and 5) and other indicators SCr,
CrCl, ACR and PCR. Frequencies for each of the stages
will be combined and pooled estimates calculated. The
Cochrane Q test and I2 statistic with its 95 % (CI) will be
used to assess heterogeneity across studies. Presence of
publication bias and other reporting bias will be assessed
with the use of the inverted funnel plot technique and the
Egger statistic will be used to test for bias. The GRADE
framework may be used to assess the quality and incon-
sistency between studies, risk of bias including publication
bias, precision of results and applicability of results to the
study population [24].
Discussion
This systematic review will synthesise research evidence
to establish whether the risk of developing CKD is rela-
tively high in young adults with IGT and gather informa-
tion on IGT progression to T2DM and development of
CKD in this age group. Strengths and limitations will be
highlighted in the identified evidence. Strength of obser-
vational data may include large sample size, high rate of
follow-up and frequency of CKD more likely to be repre-
sentative of the population at risk. Limitations may in-
clude the quality of data extracted which may not allowstudies to be combined in a meta-analysis. This may be
overcome by presenting the findings in a descriptive
manner. This review was conducted in collaboration
with an experienced librarian who helped appraise the
search criteria, refine the keywords and MeSH terms
and identify appropriate database(s). Screening and data
extraction will be conducted by three reviewers employ-
ing a data extraction form which has been reviewed and
pretested. Furthermore, this review is not limited to the
English language. To the best of our knowledge, no re-
views have been published exploring the study question;
however, if a review addressing a similar question is pub-
lished, it will be incorporated in this review and added
in a meta-analysis if feasible.
Implications of results
This systematic review will provide an updated and
quantifiable estimate of the risk of CKD in young adults
with IGT compared to those without IGT and compared
to young adults with diabetes. If it is found that the fre-
quency of CKD is elevated in young adults (aged 18 to
40 years) with IGT, then the management is likely to be
inadequate. This review may inform policy change and
implementation of preventative measures in this age
group. Furthermore, the systematic search will identify
where future research is required. For instance, this re-
view may inform a prognostic study which may be useful
in understanding the course and factors associated with
CKD development.
Additional files
Below is the link to the electronic supplementary material.
Additional file 1: Electronic search strategy used to conduct
comprehensive literature search. Electronic search of Medline for
CKD outcomes.
Additional file 2: Data extraction form adapted from Hayden et al.
[21]. Framework for prognostic studies. Tools and domains to assess risk
of bias at different stages of data extraction.
Additional file 3: Quality assessment form adapted from the
Ottawa-Newcastle scale (NOS) for assessing non-randomised
studies. Quality assessment form adapted to reflect the nature of cohort
and case–control studies related to CKD outcomes.
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